FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT	<b>OF CHANG</b>	ES IN BENEFI	CIAL OWNERSH	IΡ

OMB APPF	ROVAL								
OMB Number: 3235-02									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative

2. Conversion or Exercise Price of Derivative Security

1. Title of

Derivative Security (Instr. 3)

3. Transaction Date (Month/Day/Year)

3A. Deemed

Execution Date,

if any (Month/Day/Year)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(c). See Instruction 10.											
Name and Address of Reporting Person*     FMR LLC	2. Iss San	suer Name <b>and</b> Tick aa Biotechnolo	er or Tr ogy, I	nc.	Symbol SANA	5. Rel (Ched	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director  Officer (give title work)  See Remark 1				
(Last) (First) (Middle) 245 SUMMER STREET		ate of Earliest Trans	action (	Month	/Day/Year)						
(Street) BOSTON MA 02210 (City) (State) (Zip)	4. If <i>I</i>	Amendment, Date o	f Origin	al File	d (Month/Day/	6. Indi Line)	<u>,                                     </u>				
	n-Deriva	tive S	Securities Acq	uired	. Dis	posed of.	or Ben	eficially	/ Owned		
1. Title of Security (Instr. 3)	2. Transact Date (Month/Day	ion	2A. Deemed Execution Date,	3.	ction	4. Securities Disposed Of	Acquired	(A) or	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	01/08/2	025		S		100,000	D	<b>\$</b> 6.11 <sup>(1)</sup>	4,732,423	I	F-Prime Capital Partners Life Sciences Fund VI LP
Common Stock	01/08/2	025		S		25,000	D	\$6.5(2)	4,707,423	I	F-Prime Capital Partners Life Sciences Fund VI LP
Common Stock	01/08/2	025		S		164,912	D	<b>\$</b> 6.71 <sup>(3)</sup>	4,542,511	I	F-Prime Capital Partners Life Sciences Fund VI LP
Common Stock	01/08/2	025		S		1,000	D	\$7.26	4,541,511	I	F-Prime Capital Partners Life Sciences Fund VI LP
Common Stock									61	I	FMR Capital, Inc.
Table II	Dorivati	6.	curities Acau	irad I	Dian	acad of a	. Dana	ficially	Owned		

(e.g., puts, calls, warrants, options, convertible securities)

5. Number

Derivative

Securities

Acquired
(A) or
Disposed
of (D)
(Instr. 3, 4

and 5)

4. Transaction Code (Instr. 8)

6. Date Exercisable and

Expiration Date (Month/Day/Year)

7. Title and

Amount of Securities Underlying

Derivative Security (Instr. 3 and 4)

9. Number of

derivative Securities

Owned Following

Beneficially

Reported Transaction(s) (Instr. 4)

10.

Ownership Form: Direct (D)

or Indirect (I) (Instr. 4)

11. Nature

of Indirect Beneficial

Ownership

(Instr. 4)

8. Price of

Derivative Security (Instr. 5)

		Tal	ole II -	Deriva	tive S	Securi	ties	Acqu	ired, Dis	posed of,	or Be	rienena	ly Owne	d		
				(e.g., p	outs,	calls,	warr	ants,	options,	convertib		civirities	)			
1. Title of Derivative	2. Conversion	3. Transaction	3A. De	emed	<b>€</b> .od	V saction		um( <b>D)</b> r		rcisΩaddeeand		e Salnadres	8. Price of Derivative	9. Number of derivative	10. Ownership	11. Nature
Eseptantatio	noorf⊞Respisens	estionth/Day/Year) s transaction is the w	if any	,	Cod	(Instr.	Der	ivative urities	(Month/Day	/Year)	Secu		Security (Instr. 5)	Securities Beneficially	Form: Direct (D)	Beneficial Ownership
staff, the issu	esecurity Curity	holder of the issuer	full into	rmation reg	garding	ne numi	per(A)	hares a	nd prices at w	nich the transa	cti Se cu	rity (instr.			or Indirect . (I) (Instr. 4)	
		s transaction is the w y holder of the issuer					oer <b>ef</b> f(	hares a						pReported n requ Transaction(s)	est by the Cor	nmission
3. The price r staff, the issu	reported for this er, or a security	s transaction is the w holder of the issuer	eighted a full info	verage prior	ce of mi	ltiple tra	ıde <b>àn</b> d	tr. 3, 4 Byices r shares a	anging from \$ nd prices at w	6.20 to \$6.98. hich the transa	FMR La	LC hereby is effected.	undertakes to	• (Instr. 4) provide upon requ	est by the Cor	nmission
Remarks					-	_	_	1	1	1	1	A	1			
Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family and coulding Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family program and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares and the execution of the shareholderoits agree the program of voting common shares and the execution of the shareholderoits agree the program of voting common shares and the execution of the shareholderoits agree the program of voting common shares and the execution of the shareholderoits agree the program of the shareholderoits agree the program of the statement shall not be deemed to be on admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP, FPCPLSA) is the general partner and its investment manager. Impress Management LLC, is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain																

/s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

members of the Johnson family. FMR Capital, Inc. is a wholly owned subsidiary of FMR LLC.

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.